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ABSTRACT
The importance of androgen receptor (AR) signaling is increasingly being 
recognized in breast cancer, which has elicited clinical trials aimed at assessing the 
efficacy of androgen deprivation therapy (ADT) for metastatic disease. In prostate 
cancer, resistance to ADT is frequently associated with the emergence of androgen-
independent splice variants of the AR (AR variants, AR-Vs) that lack the LBD and 
are constitutively active. Women with breast cancer may be prone to a similar 
phenomenon. Herein, we show that in addition to the prototypical transcript, the AR 
gene produces a diverse range of AR-V transcripts in primary breast tumors. The most 
frequently and highly expressed variant was AR-V7 (exons 1/2/3/CE3), which was 
detectable at the mRNA level in > 50% of all breast cancers and at the protein level in a 
subset of ERα-negative tumors. Functionally, AR-V7 is a constitutively active and ADT-
resistant transcription factor that promotes growth and regulates a transcriptional 
program distinct from AR in ERα-negative breast cancer cells. Importantly, we provide 
ex vivo evidence that AR-V7 is upregulated by the AR antagonist enzalutamide in 
primary breast tumors. These findings have implications for treatment response in 
the ongoing clinical trials of ADT in breast cancer.
INTRODUCTION
Estrogen signaling, mediated via the estrogen 
receptor alpha (ERα), is a key determinant of the growth 
and survival of normal and the majority of malignant 
breast epithelial cells. As such, inhibition of ERα signaling 
by ERα antagonists or drugs that block the biosynthesis 
of estrogens (i.e. aromatase inhibitors) are the mainstay 
adjuvant treatments for estrogen-sensitive breast cancer, 
which encompasses approximately 70% of all cases. 
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The remaining breast cancers lack ERα and women with 
this type of disease do not gain benefit from current adjuvant 
hormone therapies. A subset of ERα-negative cancers are 
characterized by amplification or overexpression of human 
epidermal growth factor receptor 2 (HER2) and can be 
treated with HER2-targeting agents. However, 15–20% 
of breast tumors lack ERα, HER2 and a clinically relevant 
biomarker of ERα signaling, progesterone receptor (PGR); 
this subtype is termed triple-negative breast cancer (TNBC) 
[1]. TNBC is particularly aggressive and adjuvant treatment 
strategies are limited to chemotherapeutics, which are 
commonly associated with rapid relapse [2]. Identification 
of alternative therapeutic targets for TNBC is a current 
clinical imperative.
The androgen receptor (AR) is a steroid hormone 
receptor structurally related to ERα that mediates the 
action of androgen hormones, is critical for development 
of the male phenotype and has a role in modulating the 
female phenotype. AR signaling has primarily been 
studied in prostate cancer, where it plays a central role 
in both the initiation and progression of disease [3], but 
more recent studies have demonstrated the critical role 
of this pathway in breast cancer [4]. AR is expressed in 
80–90% of all breast cancers, including up to 55% of ERα-
negative breast cancers overall and up to 35% of those 
classified as TNBC [5, 6]. The role of AR in breast cancer 
appears to be dichotomous depending on ERα status and 
molecular subtype [4]; in luminal ERα-positive breast 
cancers, AR expression is associated with more favorable 
outcomes and the role of AR signaling is predominantly 
anti-proliferative, but in ERα-negative breast cancers 
the clinical implications of AR expression and activity 
remain equivocal. In certain ERα-negative breast cancer 
cell lines, AR can stimulate growth and survival [7–11]. 
Interestingly, a subset of ERα-negative/AR-positive 
cancers, sub-classified as “molecular apocrine” for 
histological reasons, exhibited transcriptomic profiles 
that were similar to those stimulated by AR signaling 
in prostate cancer cells [8, 9]. Recent studies of MDA-
MB-453, a cell line model of molecular apocrine breast 
cancer, revealed that the AR cistrome has a similar 
profile to the ERα cistrome in MCF7 breast cancer cells, 
thereby stimulating a luminal gene signature [12], and 
that AR promotes HER2 signaling by activating Wnt and 
c-MYC signaling pathways [13–15]. Collectively, these 
observations provide evidence for the hypothesis that AR 
can be an oncogene in certain ERα-negative breast cancers 
by acting as a “surrogate” ERα or by recapitulating the 
oncogenic program that stimulates growth of prostate 
cancer cells [4]. This concept is supported by studies 
demonstrating that the growth of cell line and xenograft 
models of AR-positive TNBC is inhibited by treatment 
with the AR antagonist bicalutamide, a drug historically 
developed to treat men with prostate cancer [11, 12, 14].
The concept of AR as a breast cancer oncogene, and 
the availability of effective AR-targeting agents used to 
treat prostate cancer, has elicited clinical trials assessing 
the efficacy of AR antagonists and androgen biosynthesis 
inhibitors in preventing disease progression in women 
with advanced, metastatic breast cancer. These agents, 
along with gonadotropin-releasing hormone (GnRH) 
agonists/antagonists, are components of androgen 
deprivation therapy (ADT), the current mainstay of 
treatment for men with metastatic prostate cancer. ADT 
is initially effective in most men but inevitably fails and 
the resultant disease, termed castration-resistant prostate 
cancer (CRPC), is incurable and the primary cause of 
prostate cancer mortality. The totality of research over 
the past decade has revealed that the most common 
event associated with failure of ADT is the inappropriate 
activation or maintenance of AR signaling [16]. Based on 
this knowledge, we propose that women treated with ADT 
for advanced breast cancer may be susceptible to a similar 
evolution of disease.
Androgen signaling in the “castrate” environment 
is often mediated by direct changes to AR, including 
upregulation of its expression [17], amplification of the 
AR gene [18, 19] and mutations that result in aberrantly 
active receptors [18, 20–25]. More recent research has 
demonstrated that sustained AR signaling in CRPC can also 
be driven by the emergence of C-terminally truncated AR 
variants (AR-Vs) [26–28]. These variants, which arise due 
to alternative splicing and/or structural rearrangements of 
the AR gene, have variable structures but each lacks all or 
a portion of the ligand-binding domain (LBD) [29]. This 
can produce constitutively-active (ligand-independent) 
transcription factors resistant to drugs that inhibit androgen 
production and biosynthesis (i.e. GnRH modulators, 
abiraterone) or directly target the LBD (i.e. bicalutamide 
and enzalutamide) [30]. It is now generally recognized that 
increased AR-V expression is an important mechanism 
underlying resistance to ADT and the development and 
progression of CRPC [19, 26, 31–34].
Given the arrival of AR-targeting agents to the 
breast cancer clinical arena, the heterogeneous nature of 
this disease and the dichotomous actions of AR in different 
breast cancer contexts, the question of whether AR-Vs are 
expressed in breast malignancies is critically important. 
Herein, we demonstrate that the AR-V7 variant is 
commonly expressed in primary breast cancers and breast 
cancer cell lines and provide evidence that this factor 
could promote growth and mediate resistance to ADT in a 
subset of breast tumors.
RESULTS
Diversity of AR splicing in breast cancer
An RNA-seq breast cancer dataset from The 
Cancer Genome Atlas, comprised of 1057 cancers and 
111 peri-tumoral samples of normal histology, was used 
to examine transcripts associated with the AR gene. For 
data presentation, the tumors are classified into five  sub-
groups based on the PAM50 classification system. In this 
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cohort, the prototypical, full length AR transcript (AR-FL) 
was expressed at the highest average levels in Luminal A 
and lowest levels in Basal tumor sub-groups (Figure 1A). 
This pattern was also observed in the larger METABRIC 
breast cancer cohort (1992 tumors) [35] (Supplementary 
Figure S1), indicating that the TCGA dataset adequately 
encompasses the heterogeneous scope of this disease. 
Examination of RNA sequence reads spanning canonical 
and non-canonical exons of the AR gene revealed that 
the AR-FL transcript was the predominant species 
in the majority of peri-tumoral and malignant breast 
tissues (Figure 1B). However, reads indicative of non-
canonical splicing events were also identified (Figure 1B; 
Supplementary Figure S2). The most common and more 
highly expressed non-canonical reads were those that 
spanned exons 3-CE3, evident in 544 tumors (51.5%) and 
51 peri-tumoral tissues (45.9%), which are predicted to 
be derived from transcripts encoding the AR-V7 splice 
variant. The AR-V7 transcript was most abundant in 
tumors that exhibited amplification of the HER2 oncogene, 
which are referred to as HER2-enriched (Figures 1C, 
1D and Supplementary Figure S2). Estimation of the 
amount of exon 3-CE3 splicing as a proportion of AR-
FL expression identified a subset of HER2-enriched and 
Luminal A or B tumors in which AR-V7 was detected 
at levels roughly equivalent to the canonical transcript 
(Figure 1D).
Other relatively common non-canonical splicing 
events found in the TCGA RNA-seq data and predicted 
variant receptors encoded by such events were: exon 1a-2 
(AR45; 25.0%), 3-CE1 (AR-V1, AR-V2 or AR-V4; 9.3%), 
2-CE4 (AR-V3; 16.3%), 3-CE5 (AR-V9; 13.7%) and 
6–9 (AR-V13, AR-V15 or AR-V18; 19.5%). In general, 
the number of reads for predicted AR variant transcripts 
correlated with total AR read counts and with each other 
(Supplementary Table S1 and Figure S3), indicating 
that non-canonical variant transcripts tend to increase 
concordantly with AR-FL gene transcription. Collectively, 
these data are in accord with the ENCODE and recent 
deep RNA sequencing studies, which demonstrated that 
most genes are characterized by frequent and complex 
alternative splicing [36–38].
Expression of the AR-V7 variant in clinical 
breast cancer
Given the relative abundance of AR-V7 transcripts 
compared to other AR splice variants in the TCGA dataset, 
we validated its expression in an independent cohort of 
prospectively collected primary breast cancers (n = 54), 
comprised of the expected proportion of ERα-positive 
(64.8%) and ERα-negative (35.2%) cases (Supplementary 
Table S2). Transcripts encoding AR-FL were detected in 
53 tumors (98.1%) and transcripts encoding AR-V7 were 
detected in 29 tumors (53.7%), which closely matched 
the frequency of occurrence in the TCGA cohort. Most of 
the tumors had relatively low levels of AR-V7 transcript, 
with the exception of 3 ERα-negative tumors (Figure 2A). 
Copy numbers for AR-V7 were generally < 10% of those 
for AR-FL, although 4 ERα-negative tumors, including 
the 3 with relatively high AR-V7 (colored dots) and one 
with intermediate AR-V7 expression (black dot), had 
roughly equivalent levels of the two transcripts (Figure 
2B). Similar to the TCGA dataset, a positive correlation 
between AR-V7 and AR-FL mRNA levels was observed 
(Figure 2C).
The three ERα-negative samples with relatively 
high AR-V7 transcript copy numbers had readily 
detectable AR-V7 protein by IHC (Figure 2D). 
No staining was evident in tumors that had low or 
undetectable expression of AR-V7 mRNA (Figure 
2D shows a representative negative tumor). IHC was 
done using a new rabbit monoclonal antibody (Abcam 
EPR15656) that we demonstrated to be specific for AR-
V7 by siRNA-mediated knockdown (Supplementary 
Figure S4). Dual label immunofluorescence revealed that 
AR-V7 and AR-FL proteins predominantly co-localized in 
the nuclei of breast cancer cells (Figure 2E, left panels). 
In accord with the mRNA data, the presence of AR-FL 
protein did not always correspond to the presence of AR-
V7 protein (Figure 2E, middle panels). Western blotting 
verified that in a representative sample positive for AR-
V7 by IHC and IF, a protein migrated at the expected 
molecular weight for AR-V7, confirming specificity 
(Supplementary Figure S5).
Collectively, the TCGA and our cohort indicate 
that AR-V7 is expressed in about 50% of primary breast 
tumors, is positively correlated with AR-FL expression, 
but is much less abundant than the prototypical transcript 
in the majority of cases. These data also confirm that some 
ERα-negative breast tumors have an altered pattern of AR-
V7 mRNA and protein expression in which the variant is 
present at similar levels to AR-FL.
Expression of the AR-V7 variant in cell line 
models of breast cancer
To identify an appropriate model to investigate 
AR-V7 function in breast cancer, qRT-PCR was used to 
quantify its expression in a panel of breast cancer cell 
lines. Prostate cancer cell lines 22Rv1 and VCaP, which 
express high and medium levels of AR-V7, respectively 
[19], were included as positive controls. AR-V7 transcript 
was detected in all of the breast cancer cell lines except for 
MDA-MB-231 and CAL-51 (Figure 3A), which express 
the lowest levels of AR-FL (Figure 3B). As a proportion of 
AR-FL, AR-V7 in the breast cancer cell lines ranged from 
0.4% (MCF7) to 1.1% (ZR-75–1) (Figure 3A). Similar to 
the primary breast tissue results, the levels of AR-V7 and 
AR-FL were highly correlated in breast cancer cell lines 
(Spearman r = 0.982, p < 0.0001).
We next tested whether AR-V7 protein was 
produced in breast cancer cell lines by Western blotting 
with an AR-V7-specific antibody. A band migrating at the 
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Figure 1: The diversity and frequency of AR splicing in breast cancer. A. Relative expression of AR by PAM50 subtype in 
the TCGA cohort. B. Proportion of TCGA tumor or normal samples with the indicated splicing event. Tumors were subtyped using the 
PAM50 classification system. C. Quantitation of exon 3-CE3 spanning reads, predicted to encode the AR-V7 variant, in breast cancer and 
peri-tumoral breast tissues. D. Normalized quantitation of exon 3-CE3 spanning reads in breast cancer and peri-tumoral breast tissues. Exon 
3-CE3 reads were scaled by the sum of exon 1–2 and exon 1a-2 reads (see Materials and Methods for more detail).
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Figure 2: The AR variant AR-V7 is expressed in clinical breast cancer samples. A. Expression of AR-V7 in ERα-positive (n = 35) 
and ERα-negative (n = 19) breast cancers, as determined by qRT-PCR. A Cq < 35 was used as a cut-off for determining AR-V7 positivity. AR-V7 
copy number was calculated as described in Materials and Methods. B. Ratio of AR-V7 as a proportion of AR-FL (in AR-V7-positive tumors). 
C. Correlation between AR-V7 and AR-FL copy number in AR-V7-positive tumors. Pearson’s correlation rho and p values are shown. Note that 
three tumors with high AR-V7 mRNA levels (red, blue green) or a high AR-V7:AR-FL ratio (black) are identifiable in (A)-(C) by color. D. Detection 
of AR-V7 protein by IHC in 3 breast tumors with high levels of AR-V7 mRNA expression (left). Positive staining was not detected in specimens 
that do not express AR-V7 mRNA (a representative is shown on the right). Inset images of higher magnification demonstrate strong nuclear 
staining. Colored dots enable matching of samples to (A)-(C) Scale bars are 100 microns. E. Detection of AR-V7 protein by IF and co-localization 
with AR-FL. Shown are an AR-V7 positive tumor (left), an AR-V7-negative but AR-positive tumor (middle), and a dual-negative tumor (right). 
Nuclei were stained with DAPI. In the bottom left image, a yellow arrow indicates a representative cell with strong AR-FL and AR-V7 staining 
and a red arrow indicates a representative cell with strong AR-FL staining but weak or no AR-V7 staining. Scale bars are 50 microns.
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Figure 3: Expression of AR-V7 in breast cancer cell line models. A–B. qRT-PCR was used to quantify AR-V7 (A) and AR-FL (B) in 
a panel of 8 breast cancer cell lines and 2 prostate cancer cell line controls (22Rv1 and VCaP). AR-V7 levels as a percentage of AR-FL transcript 
are shown above the columns in panel A. Values are the mean (± SEM) of triplicate samples. C. Protein lysates were collected from the 
indicated cell lines used above and subjected to Western blot analysis using AR-V7 (Precision Biosciences), AR (N20) and GAPDH (loading 
control) antibodies. Short and long exposures are shown. Note that AR-FL from 22Rv1 cells migrates more slowly because it contains two 
copies of the second zinc finger domain as a result of a genomic duplication. D. MDA-MB-453 and 22Rv1 cells were transfected with a non-
specific control siRNA (NC) or siRNAs specific for AR-FL or AR-V7. After 72 h, protein lysates were analyzed by Western blotting as in (C).
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expected molecular weight (~75 kDa) was observed in the 
two ERα-negative breast cancer lines that had the highest 
levels of AR-V7 mRNA, MDA-MD-453 and MFM-223, 
but was not apparent in lines with lower (ZR-75–1, T47D) 
or no (MDA-MB-231) expression of AR-V7 and AR-FL 
transcripts (Figure 3C). Transfection of MDA-MB-453 
cells with an AR-V7-specific siRNA resulted in loss of the 
75-kDa protein band (Figure 3D), confirming its identity.
AR-V7 exhibits constitutive, AR antagonist-
resistant transcriptional activity in breast cancer 
cells
Functional studies were undertaken to assess the 
potential biological relevance of AR-V7 in an ERα-
negative breast cancer context. The MDA-MB-453 
cell line was chosen as the primary model for further 
investigations based on our finding that it expresses 
detectable levels of AR-V7 protein. Moreover, AR-FL 
promotes the growth of MDA-MB-453 cells and research 
in this model represents a key component of the basis 
for targeting AR signaling in breast cancer [11, 12, 14, 
39]. The AR Q865H mutation, identified recently in this 
cell line [39], lies within the LBD and is therefore not 
present within the AR-V7 protein. We also performed 
limited functional analysis of AR-V7 in the MFM-223 
model, which had detectable levels of AR-V7 protein and 
represents a less well-studied model of ERα-negative, 
AR-positive breast cancer. The activity of AR-V7 was 
first investigated by measuring transactivation of AR-
responsive promoters. In MDA-MB-453 and MFM-223 
cells, the presence of androgen (DHT) was required to 
activate the AR-specific probasin reporter, and this activity 
was significantly inhibited by the AR-FL antagonists, 
bicalutamide and enzalutamide (Figure 4A). By contrast, 
AR-V7 activated the probasin reporter in the absence of 
androgen and this activity was not significantly altered by 
treatment with the AR-LBD antagonists (Figure 4A).
The functionality of AR-V7 in the MDA-MB-453 
cell line was further assessed by analyzing its subcellular 
localization. In prostate cells, AR-FL localizes to the 
cytoplasm in the absence of androgen stimulation and 
undergoes rapid nuclear translocation upon hormone 
treatment. This feature was also characteristic of the 
prototypical AR in MDA-MB-453 breast cancer cells 
(Figure 4B). By contrast, AR-V7 was predominantly 
nuclear in the absence of androgen, exhibiting minimal 
cytoplasmic staining, and this pattern was unchanged by 
the addition of androgen (Figure 4B).
AR-V7 regulates a transcriptome distinct from 
AR-FL in breast cancer cells
To investigate the target genes of AR-V7 in MDA-
MB-453 breast cancer cells, we undertook microarray 
profiling following transient over-expression of AR-V7 in 
the presence or absence of DHT (Supplementary Figure 
S6A). In the absence of androgen, AR-V7 overexpression 
significantly altered transcript levels of 47 genes compared 
to the empty vector control (Supplementary Table S3). 
Interestingly, 43/47 (91.5%) of these transcripts were 
down-regulated. In the context of DHT stimulation, 
AR-V7 over-expression resulted in significantly altered 
expression of 64 transcripts, 28 of which were common 
between the two experimental conditions and represent 
core AR-V7 targets (Supplementary Table S3). One 
striking observation was that 27/28 (96.4%) of the core 
AR-V7 targets and 70/85 (82.4%) of all AR-V7 targets 
(i.e. regulated in either the presence or absence of DHT) 
were down-regulated (Supplementary Table S3). Selected 
genes identified in the microarray were validated by qRT-
PCR following over-expression or knockdown of AR-V7 
(Supplementary Figures S6B and S6C). Interestingly, 
genes altered by AR-V7 over-expression in the presence 
or absence of DHT were largely distinct from those 
regulated by hormone treatment of non-transfected cells, 
a finding evident by both comparison of the differentially 
regulated gene sets (Figure 4C) and gene set enrichment 
analysis (Figure 4D). To determine whether the AR-
V7 gene set could be an artefact of its high transient 
expression, expression profiling was also performed in 
the context of over-expression of AR-FL. None of the 
core AR-V7 targets were significantly altered by AR-FL 
over-expression (Figure 4E). Importantly, we observed 
a highly significant overlap between the androgen-
regulated transcriptome in AR-FL-overexpressing cells 
(this study) and a previously published gene set of DHT 
response in MDA-MB-453 cells [39], further verifying 
that over-expression was not generating artefactual data 
(Supplementary Table S4). Collectively, these findings 
suggest that AR-V7 has molecular functions that are 
disparate from those of AR-FL in MDA-MB-453 cells.
Interestingly, comparison of genes regulated by 
forced over-expression of AR-V7 in MDA-MB-453 
cells (this study) versus LNCaP prostate cancer cells 
[40] revealed a complete absence of overlapping targets 
(Supplementary Table S5), further supporting the concept 
of a unique AR-V7-driven transcriptome in ERα-negative 
breast cancer. Indeed, while over-expression of AR-V7 in 
LNCaP cells resulted in changes primarily to cell cycle-
associated genes, the gene set altered by AR-V7 in breast 
cancer was highly enriched for factors involved in immune 
function and signaling (i.e. interleukins, interferons) and 
cell movement (chemokines) (Supplementary Table S6). 
Finally, we also compared transcriptomes regulated by 
AR-V7 and ERα [41] and found no substantial overlap 
(Supplementary Table S7).
AR-V7-regulated genes were examined in a large 
clinical breast cancer dataset recently published by 
Ringner and colleagues, which is comprised of multiple 
different cohorts with long-term outcome data [42]. The 
core AR-V7 gene set was more highly expressed in basal 
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Figure 4: AR-V7 is constitutively active, resistant to AR antagonists and regulates a transcriptome distinct from AR-
FL. A. MDA-MB-453 and MFM-223 cells were transfected with plasmids expressing full-length AR-FL or AR-V7 and an AR-responsive 
reporter construct and subsequently treated with 1 nM DHT, 1 μM bicalutamide and/or 1 μM enzalutamide. Luciferase activity values represent 
the mean (±SEM) of 6 biological replicates; results are representative of three independent experiments. ANOVA followed by Tukey’s multiple 
comparisons tests were used to assess changes in luciferase activity (**, p < 0.01; *, p < 0.05): for AR-FL, comparisons were with DHT; for 
AR-V7, comparisons were with vehicle (Veh). None of the treatments caused a statistically significant change in AR-V7 activity. B. MDA-
MB-453 cells grown in androgen-depleted media were transfected with GFP-tagged forms of full-length AR-FL or AR-V7 and treated with 
10 nM DHT or vehicle control (ethanol) for 24 h. Nuclei were stained with DAPI and cytoskeletons with phalloidin. Representative images 
are shown for four color channels (GFP, DAPI, phalloidin and merge). C. Venn diagram showing the overlap between genes differentially 
expressed in response to AR-V7 expression and DHT treatments. D. No association between DHT-regulated and AR-V7-regulated genes in 
the MDA-MB-453 model, as demonstrated by gene set enrichment analysis (GSEA). E. Heat map demonstrating that AR-FL over-expression 
does not alter expression of the core AR-V7 regulated gene set. F. Expression of the core AR-V7-regulated gene set according to PAM50 breast 
cancer subtype in the GOBO cohort. The gene set was highest in basal tumors compared to all other subtypes (ANOVA, followed by Tukey’s 
multiple comparisons test). G. Kaplan-Meier survival plot showing metastasis-free survival in HER2-enriched patients from the Ringner et al 
cohort (left) and disease-specific survival in HER2-enriched patients from the METABRIC cohort (right). Patients were stratified by median 
expression of the core AR-V7 regulated gene set into low and high groups. Log rank test p values: ****, p < 0.0001; *, p < 0.05.
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tumors compared to all other subtypes and lowest in 
luminal tumors (Figure 4F). Interestingly, low expression 
of this gene signature – potentially driven by high AR-V7 
activity – was predictive of metastasis in HER2-enriched 
patients (Figure 4G, left) but not other PAM50 subtypes 
(Supplementary Figure S7). This finding was validated 
in the METABRIC cohort [35], in which low expression 
of the AR-V7 signature was predictive of breast cancer-
specific death only in the HER2-enriched subtype (Figure 
4G, right; Supplementary Figure S7).
AR-V7 is involved in breast cancer cell growth 
and mediates resistance to anti-androgens
Previous studies have shown that AR-FL is required 
for optimal growth of the MDA-MB-453 cell line [12, 
14], which we recapitulated using MTT (Figure 5A) and 
Trypan Blue (Figure 5B) growth assays. Despite being 
expressed at much lower levels than AR-FL, knock-down 
of AR-V7 resulted in an equivalent growth reduction 
(Figure 5A, 5B). A distinct AR-V7-targeted siRNA 
validated these findings (Supplementary Figure S8). 
Importantly, knockdown of AR-V7 had no significant 
inhibitory effect on induction of known androgen-
regulated genes (Supplementary Figure S9), suggesting 
that it predominantly promotes growth of breast cancer 
cells through molecular activities distinct from AR-FL and 
thereby reinforcing the findings from the microarray study.
To assess whether AR-V7 could mediate resistance 
to an AR antagonist in breast cancer, we transiently 
transduced MDA-MB-453 cells with a lentivirus designed 
to over-express AR-V7 (Supplementary Figure S10) and 
assessed cell growth in response to treatment with a 
contemporary AR antagonist, enzalutamide, using Crystal 
Violet assays. Cells expressing a control protein (GFP) 
exhibited reduced growth in the presence of enzalutamide, 
whereas over-expression of AR-V7 abrogated this effect 
(Figure 5C).
Regulation of AR and AR-V7 expression by DHT 
and enzalutamide in breast cancer
To evaluate whether AR agonism or antagonism 
affects the expression and/or stability of AR-V7 in breast 
cancer, RNA and protein were isolated from MDA-
MB-453 cells treated for 24 h with DHT, bicalutamide 
or enzalutamide. Treatment with enzalutamide caused an 
accumulation of AR-FL and AR-V7 transcripts, whereas 
treatment with DHT inhibited transcription of the AR gene 
(Figure 5D). Bicalutamide, a weaker AR antagonist, did 
not alter the expression of either AR-FL or AR-V7. Western 
blotting revealed that treatment with both anti-androgens 
led to a reduction of AR-FL (Figure 5E). By contrast, 
enzalutamide caused an increase in the levels of AR-V7 
protein (Figure 5E). 
To investigate the relationship between AR 
antagonism and AR gene transcription in a more 
biologically relevant system, the response of AR and 
AR-V7 expression to enzalutamide was assessed in a 
prospectively collected cohort of primary human breast 
tumours cultured ex vivo. Expression of AR-FL was 
significantly increased in 11/14 tumours (average = 
1.42-fold) in response to treatment with enzalutamide 
(one sided t test p = 0.004) (Figure 5F, left panel). AR-
V7 was detected in 10/14 of the ex vivo cultured tumours 
and, similar to the prototypical transcript, was induced 
by enzalutamide (8/10 samples, average = 2.29-fold; one 
sided t test p = 0.019) (Figure 5F, right panel). Overall, 
these results are consistent with androgen deprivation 
therapy promoting increased transcription of the AR gene 
and concomitant accumulation of AR-V7 protein in ERα-
negative breast cancer cells.
DISCUSSION
Clinical trials are underway that repurpose ADT 
agents approved for prostate cancer to different breast 
cancer subtypes, particularly TNBC (e.g. NCT01889238, 
NCT01990209, NCT02348281, NCT02000375, 
NCT02091960, NCT00755885). These trials arose 
from the recognition that a subset of TNBCs that 
lack viable targets for therapy are positive for AR, 
combined with pre-clinical studies suggesting that AR-
FL signalling promotes growth in this context. There 
are two caveats to this approach: first, AR expression 
is used as a biomarker for patient selection but AR-
FL activity markedly varies depending on ERα status 
and molecular subtype [4]; and second, ADT in men 
inevitably leads to therapy resistant, lethal disease, but 
whether such treatment-associated selection pressure 
will occur in breast cancer is unknown. Herein, we 
present data showing that transcription of the AR gene 
in primary non-malignant and malignant breast tissues 
generates a diverse array of splice variants, particularly 
the C-terminal truncated variant AR-V7, which has been 
linked to ADT resistance in men with prostate cancer 
[27, 28, 30, 34]. Moreover, we show for the first time 
that this transcript is highly expressed at the protein 
level in a subset of ERα-negative breast cancers, and 
that treatment with the ADT agent enzalutamide can 
induce expression of the AR gene, and consequently the 
AR-V7 transcript, in MDA-MB-453 cells and primary 
breast tumours. Functional studies further confirmed 
the growth-promoting activity of AR-V7 in an ERα-
negative breast cancer context and provided an AR-V7-
regulated gene signature that predicted a worse survival 
outcome in women with HER2+ disease. Collectively, 
our data raises a cautionary note to those engaged in 
trials exploring ADT agents in women with breast cancer 
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and provides a rationale for examining the expression of 
AR-V7, or AR-V7-regulated gene(s) identified herein, 
as potential predictive biomarkers of treatment response.
AR-V7 transcript was expressed at low levels in 
about half of all breast cancers, with highest expression 
in ERα-negative cases that were HER2-enriched. It is 
noteworthy that the ratio of AR-V7 to AR-FL mRNA 
ranged from 0–100% in the TCGA cohort and 0–86% in 
our prospective cohort, a greater range than that observed 
in a collection of CRPC bone metastases that would be 
Figure 5: AR-V7 regulates the growth of MDA-MB-453 cells and response to enzalutamide. A–B. MDA-MB-453 cells were 
transfected with siRNAs specific for AR-FL and AR-V7 or a control siRNA and growth was assessed in androgen-replete media using MTT 
(A) and Trypan Blue (B) growth assays. Values are the mean (±SEM) of 3 biological replicates; results are representative of three independent 
experiments. C. MDA-MB-453 cells were transduced with lentivirus designed to overexpress AR-V7 or GFP (negative control) and cell 
growth assessed using Crystal Violet assays in response to the enzalutamide. The relative change in growth compared to vehicle control is 
shown at 6 and 9 days. Values are the mean (±SEM) of 6 biological replicates comprising two independent experiments. D. Treatment with 
AR antagonists induces AR gene transcription in MDA-MB-453 cells. Cells were grown in androgen depleted media and treated with 10 nM 
DHT, 10 μM bicalutamide, 10 μM enzalutamide or vehicle control for 24 h. AR-FL and AR-V7 mRNA was measured by qRT-PCR. Values are 
normalized to GAPDH and represent the mean (± SEM) of triplicate samples, with vehicle control treatment set to 1. Results are representative 
of three independent experiments. E. Matched samples from (D) were analyzed by Western blotting using AR-V7 (Precision Biosciences), AR 
(N20) and GAPDH (loading control) antibodies. F. Human breast tumor explants were cultured with vehicle (DMSO) or enzalutamide (50 μM) 
for 48 h. AR-FL and AR-V7 transcripts were measured by qRT-PCR and normalized to GAPDH. Values are expressed as fold-change relative to 
DMSO for each individual tumor. Statistically significant differences compared to the control treatment were assessed using a Wilcoxon signed 
rank test; p values are shown. Four of the tumors did not express AR-V7 (shown by a # symbol).
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expected to have high levels of this variant [31]. High 
levels of AR-V7 mRNA corresponded to detection of 
immunoreactive protein in our prospectively collected, 
treatment-naïve cohort, consistent with AR-V7 being 
biologically relevant. In breast cancer, AR is positively 
correlated with HER2 overexpression and reciprocal 
activation between AR and HER2 occurs in both breast 
and prostate cancer cell lines [13–15, 43]. Hence, it is 
perhaps not surprising that in the TCGA cohort the highest 
levels of AR-V7 occurred in the PAM50 HER2-enriched 
molecular subgroup. In our prospectively-collected 
validation cohort, we detected high levels of AR-V7 
transcript and protein in TNBCs as well as HER2-enriched 
cases. Importantly, these are the subtypes in which AR 
signaling is thought to be oncogenic in certain contexts, 
further highlighting the potential biological relevance of 
constitutively active AR-Vs.
Many aspects of AR-V7 functionality and AR gene 
regulation identified herein recapitulate findings in the 
prostate cancer context, which is not surprising given 
the known similarities between these two malignancies, 
particularly in terms of endocrine signaling [44]. First, 
AR-V7 exhibited ligand-independent transcriptional 
activity and could drive resistance to AR antagonists. 
Second, expression of AR-V transcripts in breast cancer 
generally tracked with that of AR-FL, a feature observed 
in prostate cancer cells and tissues [45]. Mechanistically, 
this correlation is explained by the concept that non-
canonical AR splicing is ubiquitous, such that increased 
AR gene transcription results in increased levels of AR-
V transcripts [46]. Third, the known auto-regulatory 
activity of ligand-bound AR-FL on its own gene [47] was 
functional in breast cancer cells, since DHT decreased 
whereas enzalutamide increased AR gene transcription. 
These similarities suggest that AR-V-targeted agents, 
which are under clinical development for treatment of 
prostate cancer [46], could be applicable in breast cancer 
if the clinical relevance of AR-V7 is validated.
Although we report many similarities between AR-
V7 in breast and prostate contexts, a striking difference 
was that this factor governed a gene expression program 
highly disparate from that of the prototypical receptor. In 
prostate cancer cell lines, studies aimed at elucidating the 
AR-V7-driven transcriptome have been equivocal: while 
some have suggested that this variant primarily regulates 
a classical androgen-regulated gene set [28, 30], others 
identified an AR-V7-specific gene signature enriched 
for cell cycle-associated genes and pathways [40]. An 
explanation for these potential contradictions was provided 
by the observation that the AR-V7 “specific” gene set was 
shown to display a biphasic response to signals from both 
ligand-bound AR-FL and AR-V7: more specifically, it is 
induced at lower, proliferative levels of AR-FL signalling 
output but repressed at higher, anti-proliferative levels of 
AR-FL signalling output [30]. Interestingly, the AR-V7-
regulated gene set in MDA-MB-453 cells was completely 
distinct, matching neither DHT-regulated genes in 
this cell line nor the proliferative AR/AR-V mitotic 
signature identified in prostate cancer models, but rather 
comprising factors involved in immune function and cell 
movement. Moreover, low expression of the AR-V7 breast 
cancer gene set was predictive of metastasis in patients 
with HER2-enriched cancers, supporting its biological 
relevance. The differences between the breast and prostate 
AR-V7-driven transcriptional programs demonstrates that, 
much like the canonical receptor [44, 48, 49], the activity 
of this factor is likely to be context specific, perhaps due 
to differential expression of co-regulators and pioneer 
factors that dictate transcription factor DNA binding and 
transcriptional capacity [48].
Recent studies exploiting the power of deep 
RNA sequencing have demonstrated that most genes 
are characterized by frequent and complex alternative 
splicing, which may represent a ‘readiness’ for 
adaptation to changing environmental conditions [36, 
37]. We propose that this concept is exemplified in 
prostate and breast tissues by the increased expression 
of AR-Vs (and perhaps most importantly, AR-V7) 
under conditions of androgen deprivation or direct 
AR inhibition, an adaptation that serves to sustain AR 
activity. We recently reported that a variety of AR-V 
transcripts could be detected in additional tissue types, 
including other hormone sensitive tissues such as the 
ovary, placenta and testis as well as non-reproductive 
tissues such as the colon, liver, lung, bladder and brain 
[50]. With the recent clinical trials of AR-targeted 
therapies for ovarian, peritoneal or fallopian tube cancer 
(NCT01974765) and another involving all solid tumors 
that are immunopositive for AR (NCT02144051), the 
potential for selection of AR-Vs that are able to drive 
ligand-independent growth takes on greater significance.
In summary, we demonstrate that AR-V7 is 
expressed in a subset of breast cancers and present 
evidence that this factor plays a role in regulating response 
to ADT. This concept suggests that testing for AR-V7 in 
tumors from women in current clinical trials employing 
ADT therapy, which to date have demonstrated significant 
variability in patient response, is warranted.
MATERIALS AND METHODS
Analysis of breast cancer RNA-seq data from 
the cancer genome atlas (TCGA)
Obtaining TCGA RNA-seq samples
Unprocessed RNA-seq data representing tumors and 
matched normal samples within the TCGA breast cancer 
cohort were downloaded from CGHub (July 2013 to Sep 
2014). For samples where the data was available as BAM 
files (generated by MapSplice) and not in FASTQ format, 




RNA transcript annotation was combined using 
isoforms from: 1) MISO v2.0 [51]; 2) UCSC knownGene 
[52]; 3) the Ensembl 71 gene annotation [53] and; 4) a 
manually curated list of all androgen receptor splice 
variants identified from an exhaustive literature search.
RNA-seq read mapping
The raw RNA-seq reads were processed using 
the following pipeline: 1) Map all reads to the UCSC 
hg19 (NCBI GRCh37) human genome assembly using 
Bowtie v1.0.0 with the -v 2 parameter [54] and RSEM 
v1.2.4 with the arguments —bowtie-m 100 —bowtie-
chunkmbs 500 —calc-ci —output-genome- bam [55]; 2) 
Filter the resulting BAM file to remove alignments with 
mapq scores of 0 and with a splice junction overhang 
below 6 bp; 3) Align all previously unaligned reads to 
a splice junction file with TopHat v2.0.8b [56] with the 
arguments —bowtie1 —read-mismatches 3 — read-edit-
dist 2 —no-mixed —no-discordant —min-anchor-length 
6 —splice-mismatches 0 —min- intron-length 10 —max-
intron-length 1000000 —min-isoform-fraction 0.0 —no-
novel-juncs —no- novel-indels —raw-juncs; 4) Filter the 
resulting alignments as in step 2; 5) Merge the results from 
TopHat and RSEM to generate a final BAM file.
Classification of primary tumor samples into the 
intrinsic subtypes
RNA transcript levels were normalized with the 
trimmed mean of M values (TMM) method [57] using 
a scaling factor calculated based on protein-coding 
transcripts only. Tumor samples were divided into the five 
intrinsic molecular subtypes using the fifty genes included 
in the PAM50 classifier [58], with subtypes predicted 
using the scaled centroids from pam50.robust in the 
‘genefu’ R package.
Detection of androgen receptor splice variants
All reads mapping within the AR locus were 
extracted directly from the BAM files and compared to 
the manually curated list of AR splice variants. Reads 
mapping within exons were discarded and only gapped 
reads spanning splice junctions were used as a measure of 
the presence of processed RNA variants, to exclude reads 
possibly originating from unprocessed transcripts or DNA 
contamination. AR variants containing cryptic exons were 
considered ‘detected’ in a given sample if there was at 
least one read spanning the 3′ end of the upstream exon 
and the 5′ end of the cryptic exon. Exon-skipping AR 
variants were ‘detected’ if there was one or more reads 
spanning the splice junction between the 3′ end of the 
upstream exon and the 5′ site of the exon downstream 
of the skipped exon(s). There are no junctions that are 
unique to the full-length AR transcript, so to normalize 
3-CE3 reads by AR expression (Figure 1D) the number of 
reads spanning 3-CE3 were scaled using the total number 
of reads spanning the first splice junctions (exon 1–2 or 
exon 1a-2). To avoid skewing towards high 3-CE3:AR 
ratios due to low AR expression, only samples with ≥ 10 
reads spanning exons 1–2/1a-2 were included in the graph 
shown in Figure 1D.
Reagents
Bicalutamide was obtained from AstraZeneca 
(North Ryde, NSW, Australia) and dissolved in 
ethanol. Enzalutamide (MDV3100) was obtained from 
SelleckChem (Houston, TX, USA) and dissolved in 
dimethyl sulfoxide (DMSO).
Plasmid constructs
pcDNA-AR and pcDNA AR-V7 expression 
plasmids have been described [40]. pEGFP-AR-V7 and 
pEGFP-AR were generously provided by M. Marcelli 
[59]. Lentiviral expression constructs harboring GFP and 
AR-V7 have been described [60]. The probasin (ARR3-tk-
luc), MMTV (MMTV-LUC), and PSA enhancer/promoter 
constructs have been used previously by our group [61].
Breast cancer samples
Fresh breast cancer specimens were obtained with 
written informed consent from women undergoing breast 
surgery at Burnside War Memorial Hospital or Flinders 
Medical Centre (Adelaide, SA, Australia). Ethical 
approval for this study was granted by the University 
of Adelaide Human Research Ethics Committee and the 
individual hospitals (approval numbers H-065–2005, 
H-169–2011, H-215–2011, 21.11). Excised tissue 
samples were delivered to the laboratory on ice in a 
sterile container within one hour following surgery and 
washed in culture medium comprised of phenol red-free 
RPMI. Representative pieces of tissue were fixed in 4% 
formalin in phosphate-buffered saline at 4°C overnight 
and subsequently processed into paraffin blocks. Sections 
(2 μm) were stained with hematoxylin and eosin and 
examined by a pathologist to assess histology and 
pathology.
Cell culture
MDA-MB-453, T-47D, 22Rv1, VCaP, ZR75–1, 
MDA-MB-231, MCF7 and HEK293T/17 cells were 
obtained from the American Type Culture Collection 
(Manassas, VA, USA). MFM-223, Cal-51 and Cal-148 
cells were obtained from the Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cultures 
(Braunschweig, Germany). LNCaP-95 cells were a kind 
gift from Dr. Alan K. Meeker (Johns Hopkins University). 
MDA-MB-453, T-47D, ZR75–1 and 22Rv1 cells were 
maintained in RPMI-1640 medium containing 10% 
fetal bovine serum (FBS); VCaP cells were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM) 
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containing 10% FBS, 1% sodium pyruvate, 1% MEM non-
essential amino acids and 0.1 nM 5α-dihydrotestosterone 
(DHT; Sigma, St. Louis, MO, USA); MDA-MB-231 cells 
were maintained in RPMI-1640 medium containing 5% 
FBS; MCF7 cells were maintained in Eagle’s Minimum 
Essential Medium (EMEM) containing 10% FBS, 2 mM 
L-glutamine, sodium pyruvate and 0.2 U/mL insulin; 
MFM-223 cells were maintained in EMEM containing 
10% FBS, 2 mM L-glutamine, and insulin-transferrin-
sodium selenite (ITS) supplement; Cal-51 cells were 
maintained in DMEM containing 10% FBS; Cal-148 cells 
were maintained in DMEM containing 10%FBS, 2 mM 
L-Glutamine and EGF (1ug/100mL); HEK293T/17 cells 
were maintained in DMEM containing 10% FBS and 20 
mM HEPES.
RNA extraction and quantitative RT-PCR
Extraction of RNA from cells was done as described 
[39]. RNA was extracted from breast tissue using a 
Precellys system (Sapphire Biosciences, Waterloo, NSW, 
AUS) and purified using RNeasy kits (Qiagen, Venlo, 
Limburg, Netherlands). Reverse transcription quantitative 
PCR was done as described previously [39]. Primers 
sequences are available on request. Gene expression 
was normalized to GAPDH mRNA levels. For absolute 
quantification, Ct values obtained from plasmid standards 
were used to construct Ct versus cDNA copy number 
standard curves.
Immunoblotting
Preparation of whole cell lysates from breast and 
prostate cancer cell lines and Western blotting were done 
as described previously [39]. Primary antibodies used 
were rabbit polyclonal AR-N20 (sc-816, 1:1000) (Santa-
Cruz Biotechnology Inc, Santa Cruz, CA, USA), mouse 
monoclonal AR-V7 (AG-10008, 1:1000) (Precision 
Antibodies, Columbia, MD, USA), rabbit monoclonal AR-
V7 (EPR15656, 1:1000) (Abcam, Cambridge, MA, USA) 
and GAPDH (MAB374, 1:2000) (Millipore, Billerica, 
MA, USA).
Immunohistochemistry and immunofluorescence
Immunohistochemical staining for AR-V7 
was done on serial 4 μm breast tissue sections as 
described previously [62] using the AR-V7 EPR15656 
antibody (1:200), biotinylated anti-rabbit antibody 
(1:400, DAKO Corp., Carpinteria, CA), streptavidin-
horseradish peroxidase complex (1:500, DAKO), 
and diaminobenzidine tetrahydrochloride. To analyze 
22Rv1 cells (Supplementary Figure S4), a standard 
cytospin protocol was utilized [63] followed by 
immunohistochemistry as above.
Preparation of formalin-fixed, paraffin-embedded 
tissue sections for immunofluorescence was done as 
described previously [64]. For all antigens, retrieval was 
performed in 600 mL of 10 mM Tris base and 1 mM Na-
EDTA (pH 9.0) by heating in a 1100W microwave at full 
power for 5 min and subsequently heating at 50% power 
for an additional 5 min. Primary antibodies used for 
immunofluorescence were AR-441 (M3562, 1:50, DAKO) 
and AR-V7 (EPR15656, 1:400). Primary antibodies were 
detected using secondary antibodies conjugated to either 
Alexa-Fluor 488 (A11029; Life Technologies) or Alex-
Fluor 568 (A11036; Life Technologies). Images were 
acquired sequentially on a Zeiss 700 confocal microscope 
with a pinhole aperture of 2 airy units.
siRNA knockdown of AR-V7 and AR
Small interfering RNAs were purchased from 
Ambion (Life Technologies) and had the following 
target sequences: AR (GGAACUCGAUCGUAUCAUU) 
and AR-V7 (GUAGUUGUGAGUAUCAUGA) [28]. 
An additional AR-V7 siRNA (target sequence GACCA 
GACCCUGAAGAAAG) was purchased from Thermo 
Scientific (Fremont, CA, USA). A nonspecific siRNA 
duplex (Ambion) was used as a negative control in all 
experiments. To test the specificity of the siRNAs, MDA-
MB-453 and 22Rv1 cells (6.6 × 105 cells/well in 6-well 
plates) were transfected in suspension with 100 nM siRNA 
using RNAiMax (Invitrogen, Life Technologies) and 
protein lysates were collected 72 h post-transfection and 
analyzed by immunoblotting.
Transactivation assays
Transactivation assays were performed as described 
[65].
Visualization of GFP-tagged proteins in breast 
cancer cells
MDA-MB-453 cells were seeded at a density of 6.0 
× 104 cells/well onto glass coverslips in 12-well plates. 
Once seeded, cells were transfected with 100 ng/well 
of plasmids designed to express GFP, GFP-AR or GFP-
AR-V7 by mixing plasmid DNA and polyethylenimine 
at a ratio of 1:3.1 in 0.9% sodium chloride. Cells were 
subsequently treated with 10 nM DHT or ethanol (vehicle 
control) and left overnight. The cells were fixed with 4% 
paraformaldehyde for 10 min at room temperature. Alexa-
Fluor 568 phalloidin (A12380; Life Technologies) was 
used according to the manufacturer’s protocol to visualize 
actin. ProLong Gold Antifade Reagent with DAPI (Life 
Technologies) was used as mounting media and to detect 
cell nuclei. Cells were viewed using Zeiss 700 confocal 
microscope with a pinhole aperture of 1.5 airy units.
Microarray analysis
MDA-MB-453 cells (6.6 × 105 cells/well in a 6-well 
plate) were transiently transfected with 1 μg of plasmid 
DNA designed to express AR or AR-V7 (or an empty 
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vector control) using Lipofectamine-2000. After 4 h, cells 
were treated with 1 nM DHT or ethanol (vehicle control). 
After 24 h, RNA was extracted using TRIzol (Invitrogen, 
Life Technologies) and purified using an RNeasy Mini 
Kit (Qiagen). Prior to microarray analysis, AR and AR-
V7 overexpression and evidence of efficacy of DHT 
treatment (i.e. FKBP5 induction) was confirmed by qRT-
PCR. Subsequently, RNA was analyzed using Affymetrix 
Human Gene 2.0 ST arrays by the Adelaide Microarray 
Centre, as described previously [39]. Differential gene 
expression was assessed by ANOVA, with the p-value 
adjusted using a step-up multiple test correction to control 
the false discovery rate. Adjusted p-values < 0.05 were 
considered to be significant. Raw and normalized data 
have been deposited in the Gene Expression Omnibus 
database (accession number GSE65738).
MTT assays
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl 
Tetrazolium Bromide) assays were performed on MDA-
MB-453 cells treated with siRNAs targeting AR or AR-V7. 
MDA-MB-453 cells in RPMI-1640 medium containing 
10% charcoal stripped serum (CSS) were transfected in 
suspension with 100 nM siRNA using RNAiMax (Life 
Technologies), seeded in 96 well plates (6 × 103 cells/
well) and left to adhere overnight. The following day, day 
zero and standard curve plates were assayed by adding 10 
μl of 10 mg/mL MTT (Sigma) per well and incubated at 
37°C for 4 hours. 100 μl of 20% SDS (in 0.2 M HCl) was 
then added to each well and left to solubilize overnight. 
The next day the absorbance at 570 nm in each well was 
measured using a FluoStar Omega plate reader (BMG 
Labtech, Durham, NC, USA). All experimental plates 
were treated with 10 nM DHT at day zero and assayed 
using the procedure above at the indicated time points.
Trypan blue growth assay
Trypan blue exclusion counts were performed on 
MDA-MB-453 cells treated with siRNAs targeting AR or 
AR-V7. Cells were seeded at 4 × 104 cells/well in RPMI-
1640 medium containing 10% CSSS in 24-well plates 
and transfected in suspension with 100 nM siRNA using 
RNAiMax (Life Technologies). 72 h post-transfection, day 
zero counts were taken and cells were treated with 10 nM 
DHT (vehicle control). Live and dead cells were quantified 
at indicated time points using Trypan blue.
Lentivirus packaging and transduction
Lentivirus particles designed to express GFP and 
AR-V7 were prepared using a standard third generation 
packaging system in HEK293T/17 cells. For viral 
transduction experiments, MDA-MB-453 cells were 
seeded at 1.65 × 106 cells per T25 flask and left overnight 
to adhere. The next day, cells were transduced with 
concentrated lentivirus using a MOI of 1 and 6 μg/mL 
Polybrene (Sigma) in normal growth media.
Crystal violet mitogenic assay
Cell growth of lentivirus-transduced MDA-MB-453 
cells expressing AR and AR-V7 was assessed by Crystal 
Violet assay, essentially as described [66]. Briefly, cells 
were seeded in RPMI-1640 medium containing 10% CSS 
at 1 × 105 cells/well in 24-well plates and left to adhere 
overnight. Cells were treated the next day with vehicle 
control (DMSO) or 10 μM enzalutamide. At the indicated 
time points, cells were fixed and stained with Crystal 
Violet.
Treatment of cells with AR antagonists
MDA-MB-453 cells (3 × 105 cells/well in 12-well 
plate) were seeded in phenol red-free RPMI containing 
10% charcoal-stripped FBS. After 24 h, the media was 
removed and replaced with media containing 10 nM DHT, 
10 μM bicalutamide, 10 μM enzalutamide or ethanol/
DMSO (vehicle control) for 24 h. RNA and protein 
samples were analyzed by qRT-PCR or Western blotting, 
respectively.
Ex vivo culture and hormone treatment
Primary breast tumors were cultured ex vivo as 
described previously [67] in media containing DMSO 
(vehicle control) or 50 μM enzalutamide. After 48 h of 
culture, tissues were collected and stored in RNAlater 
(Invitrogen, Life Technologies) at −80°C before being 
processed for RNA extraction as described above.
Statistical analysis
Statistical tests were done using GraphPad Prism v 
6.00 (GraphPad Software; San Diego, CA, USA).
Data and materials availability
Raw and normalized microarray data from this study 
have been deposited in the Gene Expression Omnibus 
database (accession number GSE65738).
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